生物医药ETF国泰(512290)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
439,160,649.51 |
258,938,965.41 |
-931,414,501.54 |
-1,187,681,199.56 |
| 利息合计 |
46,720.65 |
22,176.76 |
1,223,673.43 |
958,591.71 |
| 其中:存款利息收入 |
46,720.65 |
22,176.76 |
87,727.97 |
44,762.90 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-101,927,850.21 |
-215,014,459.53 |
-526,171,565.16 |
-304,876,035.63 |
| 其中:股票投资收益 |
-149,414,265.09 |
-248,241,854.47 |
-587,670,926.49 |
-339,719,342.07 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
47,486,414.88 |
33,227,394.94 |
61,499,361.33 |
34,843,306.44 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
540,022,668.47 |
473,115,255.74 |
-408,141,637.64 |
-883,944,408.70 |
| 其他收入 |
1,019,110.60 |
815,992.44 |
1,675,027.83 |
180,653.06 |
| 费用 |
21,887,485.34 |
11,619,965.49 |
24,901,184.71 |
12,636,442.24 |
| 管理人报酬 |
17,872,804.68 |
9,396,678.87 |
19,605,947.38 |
9,926,277.63 |
| 基金托管费 |
3,574,560.81 |
1,879,335.71 |
3,921,189.47 |
1,985,255.53 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
440,119.85 |
343,950.91 |
1,369,958.37 |
721,619.22 |
| 利润总额 |
417,273,164.17 |
247,318,999.92 |
-956,315,686.25 |
-1,200,317,641.80 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年